Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NYSE:ELMD NASDAQ:LUNG NASDAQ:STEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$6.72-8.2%$8.05$4.30▼$11.30$177.61M0.9325,431 shs61,381 shsELMDElectromed$26.78-0.3%$24.54$17.73▼$30.73$221.56M0.3955,829 shs991 shsLUNGPulmonx$1.25-2.0%$1.43$1.13▼$3.88$52.59M0.18481,705 shs194,963 shsSTEXBiosig Technologies$0.95-2.3%$1.42$0.70▼$14.11$172.99M1.581.90 million shs121,260 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx+3.54%-2.53%-12.54%+11.76%-2.02%ELMDElectromed+3.55%+4.47%+12.95%-7.73%+22.15%LUNGPulmonx-1.55%-0.78%-0.78%-15.33%-65.49%STEXBiosig Technologies-3.74%+27.05%-12.41%-70.36%+97,219,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$6.72-8.2%$8.05$4.30▼$11.30$177.61M0.9325,431 shs61,381 shsELMDElectromed$26.78-0.3%$24.54$17.73▼$30.73$221.56M0.3955,829 shs991 shsLUNGPulmonx$1.25-2.0%$1.43$1.13▼$3.88$52.59M0.18481,705 shs194,963 shsSTEXBiosig Technologies$0.95-2.3%$1.42$0.70▼$14.11$172.99M1.581.90 million shs121,260 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx+3.54%-2.53%-12.54%+11.76%-2.02%ELMDElectromed+3.55%+4.47%+12.95%-7.73%+22.15%LUNGPulmonx-1.55%-0.78%-0.78%-15.33%-65.49%STEXBiosig Technologies-3.74%+27.05%-12.41%-70.36%+97,219,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.67Moderate Buy$10.5056.25% UpsideELMDElectromed 3.00Buy$36.6736.94% UpsideLUNGPulmonx 2.38Hold$5.38332.01% UpsideSTEXBiosig Technologies 2.00Hold$9.00847.37% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, STEX, ELMD, and CVRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CVRXCVRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026STEXBiosig Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/30/2026LUNGPulmonx D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.004/14/2026CVRXCVRx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/9/2026STEXBiosig Technologies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $9.003/5/2026LUNGPulmonx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $5.003/5/2026LUNGPulmonx D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.002/20/2026LUNGPulmonx D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.002/17/2026CVRXCVRx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy2/13/2026CVRXCVRx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.00 ➝ $10.002/11/2026ELMDElectromed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$56.65M3.14N/AN/A$1.50 per share4.48ELMDElectromed$68.86M3.22$0.65 per share41.36$5.10 per share5.25LUNGPulmonx$90.50M0.58N/AN/A$1.08 per share1.15STEXBiosig Technologies$40K4,302.08N/AN/A$0.83 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$53.31M-$2.05N/AN/AN/A-94.10%-99.32%-45.83%5/11/2026 (Estimated)ELMDElectromed$5.15M$1.0335.70N/AN/A11.34%15.71%13.37%N/ALUNGPulmonx-$54M-$1.30N/AN/AN/A-60.09%-92.94%-39.80%N/ASTEXBiosig Technologies-$462.77M-$9.58N/AN/AN/AN/A-1,476.78%-428.30%N/ALatest LUNG, STEX, ELMD, and CVRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CVRXCVRx-$0.5043N/AN/AN/A$14.49 millionN/A4/29/2026Q1 2026LUNGPulmonx-$0.33-$0.33N/A-$0.33$20.43 million$20.59 million3/31/2026Q4 2025STEXBiosig TechnologiesN/A-$8.23N/A-$8.23N/AN/A3/4/2026Q4 2025LUNGPulmonx-$0.39-$0.2518+$0.1382-$0.25$21.73 million$22.60 million2/12/2026Q4 2025CVRXCVRx-$0.42-$0.46-$0.04-$0.46$15.75 million$16.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ASTEXBiosig TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx1.267.636.72ELMDElectromedN/A5.104.74LUNGPulmonx0.814.914.28STEXBiosig TechnologiesN/A1.681.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%ELMDElectromed40.82%LUNGPulmonx91.04%STEXBiosig Technologies7.16%Insider OwnershipCompanyInsider OwnershipCVRXCVRx13.90%ELMDElectromed10.50%LUNGPulmonx6.80%STEXBiosig Technologies52.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.43 million22.76 millionOptionableELMDElectromed1608.28 million7.36 millionOptionableLUNGPulmonx25042.24 million39.37 millionOptionableSTEXBiosig Technologies50181.14 million85.63 millionN/ALUNG, STEX, ELMD, and CVRX HeadlinesRecent News About These CompaniesStreamex Corp. to Present at the 21st Annual Needham Technology, Media, & Consumer ConferenceMay 7 at 9:00 AM | globenewswire.comBiosig Technologies (NASDAQ:STEX) CIO Sells $208,451.77 in StockMay 5 at 4:52 AM | insidertrades.comBiosig Technologies (NASDAQ:STEX) CIO Mitchell Young Williams Sells 263,863 SharesMay 4, 2026 | marketbeat.comBiosig Technologies (NASDAQ:STEX) & Check-Cap (NASDAQ:MBAI) Head-To-Head ReviewMay 2, 2026 | americanbankingnews.comStreamex Corp. Announces First Yield Dividend Distribution for GLDYApril 28, 2026 | globenewswire.comBiosig Technologies (NASDAQ:STEX) CFO Christine Marie Plummer Sells 10,922 SharesApril 18, 2026 | insidertrades.comChristine Marie Plummer Sells 10,922 Shares of Biosig Technologies (NASDAQ:STEX) StockApril 17, 2026 | marketbeat.comInsider Selling: Biosig Technologies (NASDAQ:STEX) Chairman Sells 12,759 Shares of StockApril 17, 2026 | marketbeat.comKarl Henry Michael Mcphie Sells 30,611 Shares of Biosig Technologies (NASDAQ:STEX) StockApril 17, 2026 | marketbeat.comBiosig Technologies (NASDAQ:STEX) Price Target Cut to $9.00 by Analysts at Needham & Company LLCApril 9, 2026 | marketbeat.comStreamex Corp. (STEX) Q4 2025 Earnings Call TranscriptApril 8, 2026 | seekingalpha.comStreamex Corp. Announces Webcast Details for Wednesday, April 8 Earnings and Corporate Update PresentationApril 6, 2026 | globenewswire.comStreamex Corp. Highlights Year of Progress, Files Annual Report & Announces Earnings and Corporate Update PresentationApril 1, 2026 | markets.businessinsider.comStreamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up AgreementsMarch 27, 2026 | globenewswire.comStreamex Corp.March 27, 2026 | barrons.comStreamex Corp. to Present at the 38th Annual ROTH ConferenceMarch 19, 2026 | globenewswire.comStreamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial OfficerMarch 16, 2026 | globenewswire.comMorgan Lee Lekstrom Acquires 20,000 Shares of Biosig Technologies (NASDAQ:STEX) StockFebruary 19, 2026 | insidertrades.comStreamex Corp. (NASDAQ: STEX) Co-Founder & Executive Chairman Provides Corporate UpdateFebruary 10, 2026 | globenewswire.comStreamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of DirectorsFebruary 5, 2026 | markets.businessinsider.comInsider Buying: Biosig Technologies (NASDAQ:STEX) Major Shareholder Acquires 100,000 Shares of StockFebruary 5, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026Carmax at 5-Year Lows: Is Now The Time to Buy?By Thomas Hughes | April 16, 2026Why Simply Good Foods Stock Just Had Its Worst Day in YearsBy Chris Markoch | April 10, 2026LUNG, STEX, ELMD, and CVRX Company DescriptionsCVRx NASDAQ:CVRX$6.72 -0.60 (-8.20%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Electromed NYSE:ELMD$26.78 -0.09 (-0.32%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Pulmonx NASDAQ:LUNG$1.25 -0.03 (-1.97%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Biosig Technologies NASDAQ:STEX$0.95 -0.02 (-2.28%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
